Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece

Athanasakis K, Petrakis I, Kyriopoulos J

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.3111/13696998.2013.781028

Indexing Status
Subject indexing assigned by NLM

MeSH
Antifungal Agents /economics /therapeutic use; Cost-Benefit Analysis; Decision Support Techniques; Fluconazole /economics /therapeutic use; Greece /epidemiology; Health Expenditures; Humans; Immunocompromised Host; Itraconazole /economics /therapeutic use; Models, Economic; Mycoses /epidemiology /prevention & control; Neutropenia /epidemiology; Triazoles /economics /therapeutic use

AccessionNumber
22013027268

Date bibliographic record published
01/08/2013